TY - JOUR T1 - Asthma control in asthmatics treated with extrafine or non-extrafine ICS/LABA combinations in real life setting JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P4165 AU - Gabriele Nicolini AU - Claudio Terzano AU - Giovanni Cremonesi AU - Giuseppe Girbino AU - Eleonora Ingrassia AU - Serafino Marsico AU - Luigi Allegra Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P4165.abstract N2 - BACKGROUND: The observational PRISMA study (PRospectIve Study on asthMA control) assessed the level and subsequent changes in asthma control in a 1-year period (1, 2).OBJECTIVE: To assess the level of asthma control in patients treated with a fixed combination of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA), comparing extrafine beclomethasone/formoterol (BDP/F) treatment with non-extrafine combinations (budesonide/formoterol and fluticasone/salmeterol). METHODS: Patients with non-controlled (Asthma Control Test [ACT] score <20) asthma in the first visit were analysed if they recorded a 3-month continuous therapy with an ICS/LABA fixed combination. An ACT score=25 was considered fully controlled asthma, ACT >20 controlled asthma.RESULTS: Continuous ICS/LABA combination therapy was recorded for 2093 3-month periods. In 72.6% of cases (n=1520), patients had controlled asthma (including 17.5% [n=266] with fully controlled asthma) while 27.4% remained non-controlled.Figures show the percentages of patients with fully and controlled asthma, considering both the overall period and single follow-up visits.CONCLUSIONS: An improvement in asthma control can be detected in patients treated with ICS/LABA combinations with a significant difference in favour of extrafine BDP/F as compared to non-extrafine combinations.1) Respir Med 2012;106(2):2052) Resp Res 2012;13:112. ER -